Ignite Creation Date:
2024-05-05 @ 4:45 PM
Last Modification Date:
2024-10-26 @ 9:23 AM
Study NCT ID:
NCT00306527
Status:
COMPLETED
Last Update Posted:
2019-08-14
First Post:
2006-03-22
Brief Title:
Comparison of Safety Tolerability and Immunogenicity of Influenza Vaccines in Adults and Elderly
Sponsor:
Novartis Vaccines
Organization:
Novartis
Study Overview
Official Title:
A Phase III Observer-Blind Randomized Multi-Center Study to Evaluate Safety Tolerability and Immunogenicity in a Subset Following a Single Intramuscular Dose of a Trivalent Subunit Influenza Vaccine Produced Either in Mammalian Cell Culture or in Embryonated Hen Eggs in Healthy Adult and Elderly Subjects Who Received Either One or the Other Vaccine One Year Before in the V58P4 Study
Status:
COMPLETED
Status Verified Date:
2019-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of the study is to evaluate safety tolerability and immunogenicity in a subset following a dose of a trivalent subunit influenza vaccine produced either in mammalian cells or in embryonated hen eggs in healthy adult and elderly subjects who received either vaccine one year before 2004 in the study V58P4
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| EUDRACT 2005-001902-26 | None | None | None |